Dimethandrolone undecanoate

Dimethandrolone undecanoate (also known as DMAU) is a steroid and androgen that is used in the field of medicine for its potential in male contraception. It is an anabolic steroid that is a derivative of nandrolone, and is currently under development by the National Institutes of Health (NIH) in the United States.

History

Dimethandrolone undecanoate was first described in the scientific literature in 2008. It was developed by the Contraceptive Development Branch (CDB) of the National Institute of Child Health and Human Development (NICHD), a part of the NIH.

Pharmacology

Dimethandrolone undecanoate is a prodrug of dimethandrolone (DMA), which is a potent androgen and anabolic steroid. It has been found to be effective in suppressing spermatogenesis and is being studied for its potential use in male contraception.

Clinical trials

As of 2021, dimethandrolone undecanoate is in Phase II clinical trials for use as a male contraceptive. The trials are being conducted by the NICHD and are expected to be completed by 2022.

Side effects

Potential side effects of dimethandrolone undecanoate include weight gain, acne, and changes in cholesterol levels. However, these side effects are considered to be relatively mild and are similar to those of other anabolic steroids.

See also

• List of androgens/anabolic steroids
• Male contraceptive

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian